NCT02598661Phase 2, phase 3Active not recruiting

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Study sponsor: Geron Corporation

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-10-13Actual
Enrollment · participants289Actual
Source updated2026-07-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview